Dynavax Technologies (DVAX) Given “Buy” Rating at Royal Bank of Canada

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reaffirmed by Royal Bank of Canada in a research note issued on Friday. They presently have a $25.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 42.45% from the company’s current price.

Other research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. JPMorgan Chase & Co. downgraded shares of Dynavax Technologies from an “overweight” rating to a “neutral” rating and cut their target price for the company from $31.00 to $25.00 in a research report on Wednesday, February 14th. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $27.00 target price (up from $25.00) on shares of Dynavax Technologies in a research report on Thursday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Dynavax Technologies has a consensus rating of “Hold” and an average price target of $24.67.

How to Become a New Pot Stock Millionaire

Dynavax Technologies (DVAX) opened at $17.55 on Friday. Dynavax Technologies has a 52-week low of $5.00 and a 52-week high of $24.45. The stock has a market cap of $1,082.50, a PE ratio of -9.54 and a beta of 1.05.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.32). Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 62.50%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.53 million. equities research analysts forecast that Dynavax Technologies will post -1.62 EPS for the current year.

In related news, VP David Louis Johnson sold 3,092 shares of the stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now directly owns 7,780 shares in the company, valued at approximately $144,708. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert Coffman sold 7,500 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Dynavax Technologies by 0.7% in the 4th quarter. BlackRock Inc. now owns 3,873,883 shares of the biopharmaceutical company’s stock valued at $72,441,000 after acquiring an additional 27,123 shares during the period. GMT Capital Corp raised its position in shares of Dynavax Technologies by 1.7% in the 3rd quarter. GMT Capital Corp now owns 3,057,437 shares of the biopharmaceutical company’s stock valued at $65,735,000 after acquiring an additional 52,300 shares during the period. Vanguard Group Inc. raised its position in shares of Dynavax Technologies by 10.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock valued at $19,538,000 after acquiring an additional 199,004 shares during the period. Senvest Management LLC raised its position in shares of Dynavax Technologies by 29.3% in the 4th quarter. Senvest Management LLC now owns 1,541,588 shares of the biopharmaceutical company’s stock valued at $28,828,000 after acquiring an additional 349,288 shares during the period. Finally, Deutsche Bank AG raised its position in shares of Dynavax Technologies by 2.4% in the 4th quarter. Deutsche Bank AG now owns 1,426,918 shares of the biopharmaceutical company’s stock valued at $26,682,000 after acquiring an additional 33,390 shares during the period. Institutional investors and hedge funds own 72.52% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2018/03/11/dynavax-technologies-dvax-given-buy-rating-at-royal-bank-of-canada.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply